![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Baseline NRTI Resistance in Suppressed Participants Did Not Lead to Viral Blips on Bictegravir/Emtricitabine/Tenofovir Alafenamide B/F/TAF or Dolutegravir DTG + F/TAF Through Week 48 in Study 380-4030
|
|
|
Rima K. Acosta, Hui Liu, Sean E. Collins, Hal Martin, Kirsten L. White
Gilead Sciences, Inc., Foster City, California, USA
Presented at AIDS 2020:
23rd International AIDS Conference Virtual, 6-10 July 2020
Reported by Jules Levin
![0707201](../images/070720/070720-12/0707201.gif)
![0707202](../images/070720/070720-12/0707202.gif)
![0707203](../images/070720/070720-12/0707203.gif)
![0707204](../images/070720/070720-12/0707204.gif)
![0707205](../images/070720/070720-12/0707205.gif)
![0707206](../images/070720/070720-12/0707206.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|